
|Articles|February 1, 2005
Cytoskeletal agents: future option for reducing IOP?
New Orleans—Cytoskeletal agents, which increase outflow facility in the trabecular meshwork, are one of the drug classes that could expand the pharmaceutical options available to reduce IOP, said Carl B. Camras, MD, professor, chairman, and director of the glaucoma service, department of ophthalmology, University of Nebraska Medical Center, Omaha.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
NeuroOp Guru: When proptosis isn’t thyroid eye disease
3
FDA approves Rayner’s RayOne EMV Toric intraocular lens
4
Ophthalmic innovation by the decades: The 1980s and 1990s
5